Determinar si linezolid es superior a vancomycin en el tratamiento de la neumonía nosocomial (adquirida en el hospital) debida a Staphylococcus aureus resistente a la meticilina (SARM) en sujetos adultos. Los sujetos incorporados al estudio tendrán neumonía por Staphylococcus aureus resistente a la meticilina asociada a la atención sanitaria confirmada, la cual será tratada con linezolid o vancomycin.
Subjects to receive either linezolid 600 mg IV (Intravenous) or PO (orally) q 12 h (every 12 hours) for 7-14 days, except in cases of documented bacteremia where it could be extended to 21 days based upon investigator's discretion.
Subjects to receive vancomycin 15mg/kg IV (Intravenous) q12h (every 12 hours), adjusted for renal function, for 7-14 days, except in cases of documented bacteremia where it could be extended to 21 days based upon investigator's discretion.
Buenos Aires, Buenos Aires, Argentina